Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Where Angels Feared to Tread Roger Ashby Hunter-Fleming Ltd Technology Transfer • Experience from both sides • Hunter-Fleming, an example • Working with universities HUNTER FLEMING PHARMACEUTICAL PIPELINE PROVIDERS Hunter-Fleming Ltd Mission To be a leading, highly profitable, international company supplying novel breakthrough prescription medicines to global marketing companies, in areas of significant unmet medical needs. PATENT TO PATIENT Hunter-Fleming Ltd S an o t K ot fiz er J M ar tis yn th el ab o B ay er ca er ck N ov W ye th P J& A st ra Ze ne fiS Hunter-Fleming Ltd A ve nt is A bb G S The Market 250 200 Under Licence Own Drugs 150 100 50 0 Management • Giles Vardy, Non Exec Chairman, Chairman of AIM Steering Group, former CEO of Greig Middleton, Chairman CQS Management, alternative asset management business • Dr Jim Murray, CEO: co-founder of Shire, 29 years in Pharma industry • Professor Ernst Wulfert, CSO: former Research Director UCB responsible for the development of three blockbuster drugs – Keppra, Zyrtec, enofibrate • Dr. John Fox, Managing Director: Head of Planning at Shire, 20 years in pharmacology & clinical research • Neil Hockaday, FD: COO HSBC Corporate Banking Hunter-Fleming Ltd University Collaborations • • • • • • • • • Hunter-Fleming Ltd Bristol Belfast Southampton St Marianna Hospital, Medical School, Kawasaki Loyola, Chicago CNAM, Paris Kyoto Pharmaceutical University, Japan Tromso, Norway Strathclyde/Glasgow Business Model VALUE C NDA, drug filing B “Innovations Break Point” Basic Discovery A COST Basic Research ACADEMIA Innovation HF Hunter-Fleming Ltd Drug Development BIG PHARMA Integrated Therapies anti-neurodegenerative drugs (brain inflammatory diseases) HF 0220 Neurosciences Immunology & Inflammation (RA, Type I diabetes, (neurodegenerative diseases, AD, PD, stroke, MS…) asthma, rhinitis, cancer..) Cardiovascular & Metabolic Disorders (CHD, MI, Diabetes…) Anti-diabetic HF 1020 Hunter-Fleming Ltd Novel cytoprotective drugs brain, heart, kidney HF 0220 “follow-ups” Portfolio Preclinical HF0220 Alzheimer’s Disease HF0220 2nd generation HF1020 IBD, RA Type I Diabetes HF0699 Head Injury/Stroke HF0420 Neuro Protective/Alzheimer’s disease HF0299 Metabolic bone disease HF0723 Oncology Hunter-Fleming Ltd Phase I Phase II Phase III WHY ? • Access to blue sky research • Access to intellectual property • Access to ongoing research output FACT • British Telecom research spend £30m pa • Bristol University, • UCL, Imperial College, • Southampton University - £500m pa ACADEMIA Solutions seeking applications INDUSTRY Paucity of innovative knowledge cf Pharma 50% all new medicines in-licensed KEY ISSUES • • • • • Point of contact Executive authority Ability to deliver – Willing scientists - Secured IP Continuity Deal Breakers • Valuation of IP and / or Know how • Limitation of management expertise Decision • Licence OR • Start up new company Hunter-Fleming • • • • • • • • Mature management team Proven track record Understand university’s modus operandi Enduring partnership Virtual circle taking IP to market Financial returns to all- University - Research Staff - H-F shareholders